Latest News - Phase 3/4 Trials

Tuesday, October 23, 2018

LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infections

Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study, Short and…

Read the full story

Thursday, October 11, 2018

Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acne

Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) …

Read the full story

Thursday, October 11, 2018

Galderma Ups Its Aesthetic R&D Game

Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology p…

Read the full story

Tuesday, October 02, 2018

Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials

Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…

Read the full story

Tuesday, September 18, 2018

FDA Clears Sebacia Microparticles for Laser-Based Acne Treatment

Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Se…

Read the full story

Monday, September 17, 2018

UCB: Study Data for Cimzia and Bimekizumab Presented at EADV

UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along wit…

Read the full story

Wednesday, September 12, 2018

Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foam

Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline resul…

Read the full story

Tuesday, August 21, 2018

MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasis

MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from…

Read the full story

Thursday, July 26, 2018

Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpoints

Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study ach…

Read the full story

Monday, July 02, 2018

XELJANZ Receives EU Marketing Authorization for Adults with Active PsA

The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adul…

Read the full story

Friday, June 08, 2018

PellePharm Presents New Data in BCC

PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs a…

Read the full story

Friday, June 08, 2018

Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumab

Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) …

Read the full story

Tuesday, May 29, 2018

FDA Approves Cimzia for Moderate to Severe Plaque Psoriasis

The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment…

Read the full story

Wednesday, March 21, 2018

Sun Pharma: FDA Approves Ilumya for Adult Psoriasis

The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Il…

Read the full story

Thursday, February 15, 2018

Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meeting

Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include…

Read the full story
Load More